Breast Cancer Therapy with Novel Drug Delivery Approach

Technology Overview

Breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012 (second most common cancer overall). This represents about 12% of all new cancer cases and 25% of all cancers in women.

This nanomedicine based drug delivery approach, provides selective delivery of targeted chemotherapy agents, minimising side effects and developing pharmacokinetic properties, thus improving quality of life for patients. The nanomedicine has a special water-soluble bio-compatible macromolecular carrier that contains a covalent bond with the active drug agent, thus preventing the problem of burst , providing a better side-effect profile .

Technology Features & Specifications

This technology is targeted for breast cancer treatment: special polymeric carrier and linker, transporting the medicine directly to the tumour. The system can deliver higher amounts and multiple drugs per dose minimising side effects and increasing efficacy, benefiting patients.

Common polymeric carriers in the market can only accommodate maximum two molecules of cargo, whereas this system can carry multiple attachments with a degree of freedom on polymer length. 

Potential Applications

  • Cancer treatment drugs
  • Research, on targeted cancer treatment drugs with similar polymeric carriers and linkers

Market Trends and Opportunities

Statistics display a projection of the top 10 therapeutic areas globally and projected CAGR (fee-based) from 2015 to 2020. During this time, breast cancer is expected to have a compound annual growth rate of 13 per cent.

Indicated in a report by Statista, there will be 6 breast cancer treatment drugs in the top 20 revenue-generating cancer drugs in 2020, and their revenue share out of these top 20 cancer drugs is projected to be USD20 billion. 
In 2014, out of the top 10 cancer medicines, there are 2 breast cancer treatment drugs that have generated a revenue of USD8.4 billion. 

Customer Benefits

  • Increased quality of life for patients
    • Better side-effects profile
    • Covalent bond between polymeric carrier and drug, thus no burst problem. Drug is delivered smoothly over time, with no sudden peaks.
  • Reduced treatment time
    • More hydrophilic structure compared to traditional cancer treatment drugs, thus more drugs at one time.
    • Extended half-life of active ingredient
  • Higher chance of eliminating cancer cells
    • More drugs at one time due to its larger therapeutic window
  • Shorter time to finalise clinical trials for clinical use in treatments
    • Active ingredient already passed Phase III clinical trials and available for clinical use.
    • Original drug has been in use successfully for several years.
  • Delivery method can be used with different drugs for treatment of other cancers
    • Same polymeric carrier, same and different linkers, different active ingredients
    • Tests have to be conducted with new combinations of carrier, linkers and active ingredients.

Make an Enquiry